| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | Giredestrant + Anastrozole + Palbociclib - (coopERA) | Breast Cancer | Phase 2 | Oral | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-09) | 1L Head and Neck Squamous Cell Carcinoma | Phase 2 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-07) | Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-06) | 1L Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-05) | Neoadjuvant / Adjuvant Non-Small Cell Lung Cancer | Phase 2 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-04) | 2L+ PD-L1+ Cervical Cancer | Phase 2 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab and TECENTRIQ (atezolizumab) - CITYSCAPE | Non-small cell lung cancer (NSCLC) | Phase 2 | Intravenous infusion | Oncology | |
| Roche Holding AG ADR | Pegozafermin - (ENTRIGUE) | Severe hypertriglyceridemia | Phase 2 | Data Released | Subcutaneous | Endocrinology |